v3.26.1
Strategic Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2022
Nov. 30, 2019
May 31, 2018
Apr. 30, 2018
Feb. 28, 2018
Mar. 31, 2017
Mar. 31, 2026
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Aug. 31, 2023
Upon Achievement of Specified Development and Regulatory Milestones | Related Party                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Milestone payments, contingent amount             $ 50,000,000.0          
Microchips Biotech, Inc.                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Payment of additional consideration             0       $ 1,250,000  
Microchips Biotech, Inc. | Upon Achievement of Specified Development and Regulatory Milestones                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Milestone payments   $ 46,500,000                    
Current portion of contingent consideration   $ 55,000,000.0                    
ADVA Tec Agreement | Upon Achievement of Specified Development and Regulatory Milestones                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Milestone payments           $ 14,600,000            
ADVA Tec Agreement | Maximum                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Percentage of royalty rate           10.00%            
ADVA Tec Agreement | Minimum                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Percentage of royalty rate           1.00%            
Douglas License Agreement | Upon Achieving Certain Development Milestones                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Sales based milestones amount                       $ 5,250,000
Douglas License Agreement | Upon Achieving Certain Commercial Milestones                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Sales based milestones amount                       $ 64,000,000.0
Hennepin License Agreement | Clinical and Regulatory Milestones                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Maximum potential milestone payments $ 6,250,000                      
Hennepin License Agreement | Sales Milestones                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Maximum potential milestone payments $ 45,000,000.0                      
Licensing Agreements | Related Party                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Milestone payments, contingent amount             1,000,000.0          
Licensing Agreements | ADVA Tec Agreement | Upon Reaching Certain Worldwide Net Sales Milestones                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Milestone payments           $ 20,000,000.0            
Licensing Agreements | Upon Achieving Certain Development Milestones | Maximum | Related Party                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Milestone payments, contingent amount               $ 500,000     300,000  
Licensing Agreements | Upon Achieving Certain Commercial Milestones | Related Party                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Milestone payments, contingent amount             850,000          
Licensing Agreements | Upon Achieving Certain Commercial Milestones | Upon Achievement of Specified Development and Regulatory Milestones | Related Party                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Milestone payments, contingent amount           $ 1,200,000            
Licensing Agreements | Licensed Product or Process for Vaginal or Urological Use | Related Party                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Milestone payments, contingent amount             250,000          
Assignment Agreement | Upon Achieving Certain Clinical and Regulatory Development Milestones | Related Party                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Milestone payments, contingent amount             1,100,000          
Merger Agreement                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Maximum potential milestone payments     $ 15,500,000                  
Milestone payments     3,200,000                  
Pear Tree Pharmaceuticals, Inc. | Sales Milestones                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Maximum potential milestone payments     $ 47,000,000.0                  
Juniper Pharmaceuticals, Inc                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Upfront license fee paid       $ 250,000                
Potential annual license maintenance fee payments, thereafter       100,000                
Juniper Pharmaceuticals, Inc | Clinical and Regulatory Milestones                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Maximum potential milestone payments       13,500,000                
Juniper Pharmaceuticals, Inc | Sales Milestones                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Maximum potential milestone payments       $ 30,300,000                
License and Collaboration Agreement                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Milestone payments, contingent amount         $ 18,000,000.0              
License and Collaboration Agreement | Upon Achieving Certain Commercial Milestones                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Milestone payments, contingent amount         $ 100,000,000.0   1,000,000.0          
Organon                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Upfront license fee paid             12,800,000     $ 10,000,000.0    
Sales based milestones amount             $ 180,000,000.0          
Milestone payments, reimburse amount, PDUFA fees and other manufacturing expenses                 $ 1,000,000.0      
First commercial sale amount                 $ 1,800,000      
Advanced written notice period             120 days          
Bayer | Royalty Revenue | Collaborative Arrangement                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Upfront license fee paid             $ 1,000,000.0          
Former Stockholders of MBI | Microchips Biotech, Inc.                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Cash paid to stockholders' representative                     $ 75,000  
Catalent and MilanaPharm | Licensing Agreements                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Milestone payments, contingent amount             $ 1,000,000.0